Maryland Settles With Indivior Over Opioid Marketing
The state reached a finalized settlement with the drug maker over alleged improper marketing and monitoring of suspicious orders.
Updated on Nov. 19, 2026 in Health

Live Poll
Do you trust drug companies to market their medications responsibly?
Maryland finalized a settlement with drug manufacturer Indivior, which agreed to limit promotional activities and bar sales pay tied to opioid use disorder product volume. The settlement includes a cash payment and $2 million in treatment medication for opioid use disorder.
Why it matters
The state alleged that Indivior improperly marketed its products and failed to monitor suspicious orders, and the settlement directs funds toward treatment and abatement efforts. The injunctive terms require promotions to be truthful and not promote misuse of the company's products.
The figures come from a consent judgment entered in the Circuit Court for Frederick County, which sets out a $3.5 million total settlement including over $1.5 million in opioid abatement funds and $2 million in treatment medication. The extraction does not specify how the abatement funds will be divided among Maryland and its subdivisions.
The players
Indivior
Indivior is a pharmaceutical company that manufactures treatments for opioid use disorder.
The details
Maryland filed a complaint on November 6, 2026 against Indivior, alleging improper marketing of its products and failure to monitor suspicious orders. The consent judgment was entered in the Circuit Court for Frederick County and includes a cash payment, treatment medication and truthful-promotion requirements.
Timeline
November 6, 2026: Maryland files its complaint against Indivior.
November 19, 2026: The Attorney General announces the finalized settlement.
Big Picture
The settlement follows the pattern of state opioid abatement agreements that direct funds toward treatment and impose marketing restrictions on manufacturers. It applies those terms to a manufacturer of medications used to treat opioid use disorder.
Residents seeking treatment for opioid use disorder may see additional treatment medication made available through the settlement's $2 million allocation. The truthful-promotion requirements mean the company's marketing must avoid promoting misuse of its products.
The takeaway
State settlements like this one tie corporate penalties to treatment access and restrict how manufacturers market addiction-related medications. Readers tracking opioid policy can watch how abatement funds are distributed across Maryland's jurisdictions.
Further reading
For related coverage, see Substance Abuse reporting on opioid treatment and enforcement.
Source note: This article includes information reported by The Bay Net.
Live Poll
Do you trust drug companies to market their medications responsibly?






